Canagliflozin
- Generic Name
- Canagliflozin
- Brand Names
- Invokamet, Invokana
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25FO5S
- CAS Number
- 842133-18-0
- Unique Ingredient Identifier
- 6S49DGR869
- Background
Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise .
It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , .
Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
- Indication
This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus .
Another indication for canagliflozin is the prevention of major cardiovascular events (myocardial infarction, stroke, or death due to a cardiovascular cause) in patients with type 2 diabetes, as well as hospitalization for heart failure in patients with type 2 diabetes.
In addition to the above, canagliflozin can be used to lower the risk of end-stage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus, diabetic nephropathy, and albuminuria.
It is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis .
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Major Adverse Cardiac Events, Type 2 Diabetes Mellitus, Doubling of serum creatinine
SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05764811
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
- Conditions
- Type 2 Diabetes Mellitus With Complication
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2022-08-24
- Target Recruit Count
- 80
- Registration Number
- NCT05513729
- Locations
- 🇨🇳
First Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shannxi, China
Renal Mechanism of SGLT2 Inhibition
- Conditions
- Type 2 DiabetesDiabetic Kidney Disease
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 40
- Registration Number
- NCT05507892
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Canagliflozin Targeting Vascular Inflammation
- Conditions
- Diabetes Type 2Coronary Artery Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Ottawa Heart Institute Research Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT05427084
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
- Conditions
- Type 2 Diabetes Mellitus With Complication
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2022-09-21
- Target Recruit Count
- 80
- Registration Number
- NCT05422092
Canagliflozin and Myocardial Fibrosis
- Conditions
- Type 2 DiabetesCardiovascular DiseasesCardiac Perfusion Defect
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT05367063
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Canagliflozin in Patients With Acute Decompansted Heart Failure
- Conditions
- Chronic Heart FailureAcute Heart FailureDiabetes Mellitus
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 142
- Registration Number
- NCT05364190
- Locations
- 🇪🇬
National heart institute, Giza, Egypt
Cognitive Protective Effect of Newer Antidiabetic Drugs
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 100
- Registration Number
- NCT05347459
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Safety and Efficacy of Canagliflozin in Advanced CKD
- Conditions
- CKD Stage 4ESRDCKD Stage 5
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 44
- Registration Number
- NCT05309785
- Locations
- 🇨🇦
McGill University Health Center, Montreal, Quebec, Canada
Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV.
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- xiaolong zhao
- Target Recruit Count
- 218
- Registration Number
- NCT05135039
- Locations
- 🇨🇳
Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV: A Randomized Controlled Trial., Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.